GSK.L vs MRK
GSK.L: A global biopharma leader specializing in vaccines and specialty medicines to address complex infectious diseases, HIV, and immune-mediated conditions. MRK: Merck is a leading global biopharmaceutical company known for its dominant oncology portfolio and a diversified animal health business.
Side-by-side fundamentals
| Metric | GSK.L | MRK | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £19.10 | $128.33 | |
| Market cap as of 2026-08-06 | n/a | $317.0B | |
| P/E as of 2026-08-06 | n/a | 99.83 | |
| PEG as of 2026-08-06 | n/a | 4.91 | |
| Net margin as of 2026-08-06 | n/a | +4.8% | |
| Gross margin as of 2026-08-06 | n/a | +77.3% | |
| Operating margin as of 2026-08-06 | n/a | +9.6% | |
| ROE as of 2026-08-06 | n/a | +17.9% | |
| ROA as of 2026-08-06 | n/a | +7.0% | |
| Debt / equity as of 2026-08-06 | n/a | 1.07 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +4.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +3.1% | |
| Dividend yield as of 2026-08-06 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-06 | n/a | 0.20 | |
| 1-year return as of 2026-08-03 close | +36.7% | +58.8% | MRK higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.